Type I glutaric aciduria, part 1: Natural history of 77 patients

被引:229
作者
Strauss, KA [1 ]
Puffenberger, EG [1 ]
Robinson, DL [1 ]
Morton, DH [1 ]
机构
[1] Clin Special Children, Strasburg, PA 17579 USA
来源
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS | 2003年 / 121C卷 / 01期
关键词
type I glutaric aciduria; micrencephalic macrocephaly; basal ganglia injury;
D O I
10.1002/ajmg.c.20007
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Type I glutaric aciduria (GA1) results from mitochondrial matrix flavoprotein glutaryl-CoA dehydrogenase deficiency and is a cause of acute striatal necrosis in infancy. We present detailed clinical, neuroradiologic, molecular, biochemical, and functional data on 77 patients with GA1 representative of a 14-year clinical experience. Micrencephalic macrocephaly at birth is the earliest sign of GA1 and is associated with stretched bridging veins that can be a cause of subdural hematoma and acute retinal hemorrhage. Acute striatal necrosis during infancy is the principal cause of morbidity and mortality and leads to chronic oromotor, gastroesophageal, skeletal, and respiratory complications of dystonia. Injury to the putamen is heralded by abrupt-onset behavioral arrest. Tissue degeneration is stroke-like in pace, radiologic appearance, and irreversibilty. It is uniformly symmetric, regionally selective, confined to children under 18 months of age, and occurs almost always during an infectious illness. Our knowledge of disease mechanisms, though incomplete, is sufficient to allow a rational approach to management of encephalopathic crises. Screening of asymptomatic newborns with GA1 followed by thoughtful prospective care reduces the incidence of radiologically and clinically evident basal ganglia injury from approximately 90% to 35%. Uninjured children have good developmental outcomes and thrive within Amish and non-Amish communities. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:38 / 52
页数:15
相关论文
共 47 条
  • [1] Inflammatory mediators and modulation of blood-brain barrier permeability
    Abbott, NJ
    [J]. CELLULAR AND MOLECULAR NEUROBIOLOGY, 2000, 20 (02) : 131 - 147
  • [2] Diagnosis and management of glutaric aciduria type I
    Baric, I
    Zschocke, J
    Christensen, E
    Duran, M
    Goodman, SI
    Leonard, JV
    Müller, E
    Morton, DH
    Superti-Furga, A
    Hoffmann, GF
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 1998, 21 (04) : 326 - 340
  • [3] GLUTARIC ACIDURIA TYPE-1 - BIOCHEMICAL INVESTIGATIONS AND POSTMORTEM FINDINGS
    BENNETT, MJ
    MARLOW, N
    POLLITT, RJ
    WALES, JKH
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1986, 145 (05) : 403 - 405
  • [4] BERRY MM, 1999, GRAYS ANATOMY, P1186
  • [5] Binienda ZK, 2001, ANN NY ACAD SCI, V939, P359
  • [6] Brodal A., 1981, NEUROLOGICAL ANATOMY, Vthird, P180
  • [7] On the mechanisms of neuroprotection by creatine and phosphocreatine
    Brustovetsky, N
    Brustovetsky, T
    Dubinsky, JM
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 76 (02) : 425 - 434
  • [8] Glutaryl-CoA dehydrogenase deficiency in Spain:: Evidence of two groups of patients, genetically, and biochemically distinct
    Busquets, C
    Merinero, B
    Christensen, E
    Gelpí, JL
    Campistol, J
    Pineda, M
    Fernández-Alvarez, E
    Prats, JM
    Sans, A
    Arteaga, R
    Martí, M
    Campos, J
    Martínez-Pardo, M
    Martínez-Bermejo, A
    Ruiz-Falcó, ML
    Vaquerizo, J
    Orozco, M
    Ugarte, M
    Coll, MJ
    Ribes, A
    [J]. PEDIATRIC RESEARCH, 2000, 48 (03) : 315 - 322
  • [9] Breaking down the walls:: Thoughts on the scholarship of integration
    Dauphinée, D
    Martin, JB
    [J]. ACADEMIC MEDICINE, 2000, 75 (09) : 881 - 886
  • [10] DUNCAN JS, 2000, BRAIN MAPPING DISORD, P317